Loading clinical trials...
Loading clinical trials...
An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis
Conditions
Interventions
APD334
Locations
9
United States
Gastroenterology and Hepatology, UC Davis Medical Center
Sacramento, California, United States
Baylor College of Medicine
Houston, Texas, United States
Texas Liver Institute
San Antonio, Texas, United States
Swedish Medical Center
Seattle, Washington, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Start Date
December 29, 2017
Primary Completion Date
January 31, 2019
Completion Date
January 31, 2019
Last Updated
March 24, 2022
NCT07304843
NCT07449793
NCT06755541
NCT05751967
NCT05749822
NCT07296458
Lead Sponsor
Arena Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions